Daniel Citterio received his Doctoral degree in Natural Sciences from the Swiss Federal Institute of Technology (ETH) in Zurich (Switzerland) in 1998. From 1998-2002, he was a postdoctoral researcher at Keio University with Prof. Koji Suzuki. Upon return to Switzerland, he worked as a researcher at ETH, before joining Ciba Specialty Chemicals Inc.. In 2006, he moved back to Keio University, where he became a tenured Associate Professor in 2009 and Professor in 2014. In 2016, he has been admitted as a Fellow of the Royal Society of Chemistry (RSC). He serves as a co-Editor-in-Chief of the journal Sensors and Actuators B: Chemical, as well as on the Editorial Advisory Board of ACS Sensors. In 2022, he has been awarded the Chemical Society of Japan Award for Creative Work. His research is focusing on the development of chemical sensors and biosensors. More recently, his research team is strongly engaged in the development of microfluidic paper-based analytical devices (µPADs) for low-cost point-of-need applications.
Analytical Assays on Paper Platforms: As Simple as Possible
Friday, 6 October 2023 at 09:30
Add to Calendar ▼2023-10-06 09:30:002023-10-06 10:30:00Europe/LondonAnalytical Assays on Paper Platforms: As Simple as PossibleLab-on-a-Chip and Microfluidics Asia 2023 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
There is a continuously growing demand for analytical assays that can be performed on-site by minimally trained operators without the need for sophisticated laboratory equipment and reagent handling. In this context, (microfluidic) paper-based analytical devices (µ)PADs, including lateral-flow immunoassays (LFIAs), have gained significant attention, particularly for point-of-care testing in medical diagnostics. Over the past few years, we have demonstrated that certain analytical assays conventionally depending on benchtop instruments can be implemented into simple paper platforms not requiring any reagent handling. Examples include paper-based devices for the naked eye “calibration-free” colorimetric semiquantitative analysis of clinically relevant parameters that can be operated by minimally trained users with minimal risk of incorrect result misinterpretation. The presentation will also introduce one of our latest efforts towards boosting assay sensitivity on paper by adapting the CRISPR/Cas system to a paper-based analytical platform in the form of a simple, rapid, and highly sensitive detection method for non-nucleic acid targets by integrating CRISPR/Cas12a and an enzyme-linked immuno-sorbent assay (ELISA).